DiogenX
Marseille
About DiogenX
DiogenX is a preclinical stage biotech company, specializing in the development of pancreatic beta-cell modulators for the treatment of Type 1 (T1D) and Type 2 Diabetes (T2D). The company, which also has research labs in Nice, France, aims to discover and develop a candidate molecule that regenerates pancreatic insulin-producing cells in patients with diabetes, offering benefits in terms of quality of life and survival. It was discovered in the laboratory of Dr. Patrick Collombat (Inserm, CNRS, Nice University) in France, DiogenX is developing an innovative therapy with the potential to be the first beta-cell regeneration drug for diabetes.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $41.9M
- Funding stage: Early Stage Venture
- Last round: Series A (May 2023)
- Website: diogenx.com
Industries & Categories
Biotechnology, Life Science
Social Profiles
Canonical: https://fsome.com/organization/diogenx-124146 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.